IOBT Logo

IO Biotech, Inc. (IOBT) 

NASDAQ
Market Cap
$77.74M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
314 of 776
Rank in Industry
186 of 433

Largest Insider Buys in Sector

IOBT Stock Price History Chart

IOBT Stock Performance

About IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single …

Insider Activity of IO Biotech, Inc.

Over the last 12 months, insiders at IO Biotech, Inc. have bought $10,125 and sold $1.89M worth of IO Biotech, Inc. stock.

On average, over the past 5 years, insiders at IO Biotech, Inc. have bought $24.66M and sold $1.89M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Burkavage Brian (Chief Accounting Officer) — $10,125.

The last purchase of 5,000 shares for transaction amount of $5,175 was made by Burkavage Brian (Chief Accounting Officer) on 2023‑11‑22.

List of Insider Buy and Sell Transactions, IO Biotech, Inc.

2024-07-26Sale10 percent owner
23,478
0.0362%
$1.31$30,787-7.75%
2024-07-25Sale10 percent owner
51,522
0.0774%
$1.33$68,339-11.19%
2024-05-10Sale10 percent owner
658,809
0.8518%
$1.22$802,495-17.33%
2024-02-09Sale10 percent owner
658,809
0.8023%
$1.50$988,411-13.19%
2023-11-22PurchaseChief Accounting Officer
5,000
0.0076%
$1.03$5,175+41.36%
2023-11-21PurchaseChief Accounting Officer
5,000
0.0074%
$0.99$4,950+51.03%
2023-08-09Purchase10 percent owner
2.47M
9.534%
$2.02$5M-18.06%
2023-08-09Purchase10 percent owner
3.16M
11.4408%
$1.90$6M-18.06%
2023-03-17PurchaseChief Financial Officer
25,000
0.1017%
$2.32$58,018-8.59%
2021-11-09Purchase10 percent owner
2.14M
51.9475%
$14.00$30M-62.27%
2021-11-09Purchase10 percent owner
325,000
7.8787%
$14.00$4.55M-62.27%
2021-11-09Purchase10 percent owner
650,000
15.7574%
$14.00$9.1M-62.27%
2021-11-09Purchasedirector
650,000
15.7574%
$14.00$9.1M-62.27%
2021-11-09Purchase10 percent owner
325,000
7.8787%
$14.00$4.55M-62.27%
2021-11-09Purchasedirector
75,000
1.8182%
$14.00$1.05M-62.27%
2021-11-09Purchasedirector
325,000
7.8787%
$14.00$4.55M-62.27%

Insider Historical Profitability

<0.0001%
Novo Holdings A/S10 percent owner
4354449
6.6096%
$1.1824<0.0001%
Burkavage BrianChief Accounting Officer
11500
0.0175%
$1.1820
Lundbeckfond Invest A/S10 percent owner
6049452
9.1824%
$1.1810<0.0001%
Vivo Capital IX, LLC10 percent owner
3157894
4.7933%
$1.1820<0.0001%
Nielsen Jackdirector
3015545
4.5773%
$1.1810<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Vivo Capital$10.68M9.376.17M0%+$00.93
Novo Holdings A/S$8.8M7.725.09M-11.46%-$1.14M0.62
Samsara Biocapital Llc$6.3M5.533.64M0%+$00.98
PFM Health Sciences$4.05M3.552.34M0%+$00.11
Morgan Stanley$3.8M3.342.2M-3.7%-$146,095.05<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.